Corey McCann, Pear Therapeutics CEO

Pear Ther­a­peu­tics touts Q2 growth while scal­ing back full-year goals and chop­ping 9% of staff

Pear Ther­a­peu­tics set some am­bi­tious goals back in March, pre­dict­ing a five-fold boost in rev­enue and a surge in new pre­scrip­tions for its dig­i­tal ther­a­peu­tics. Now the com­pa­ny is scal­ing back those es­ti­mates and chop­ping 9% of its work­force — an all-too-com­mon oc­cur­rence in biotech late­ly.

CEO Corey Mc­Cann un­veiled Pear’s Q2 num­bers on Thurs­day, tout­ing a 20% quar­ter-over-quar­ter rev­enue growth to­tal­ing $3.3 mil­lion. That’s more than dou­ble what the com­pa­ny made in Q2 2021, and Mc­Cann thinks the team could see a near­ly four-fold jump in rev­enue this year, falling in the range of $14 mil­lion to $16 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.